StockNews.AI
ARDX
StockNews.AI
201 days

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

1. Ardelyx will hold a conference call on February 20, 2025. 2. The call will discuss 2024 financial results and updates. 3. Ardelyx has two commercial products approved in the U.S. 4. Tenapanor has an NDA submitted in China for hyperphosphatemia. 5. Kyowa Kirin and Knight Therapeutics are commercial partners.

Earnings
0%Current Return
VS
-0.53%S&P 500
$5.3601/30 04:33 PM EDTEvent Start
$5.3601/31 10:59 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming call may provide insights but lacks immediate news. Historical calls often have limited lasting impact.

How important is it?

The announcement indicates ongoing operations but lacks significant news. Past earnings calls provide mixed impacts.

Why Short Term?

The details discussed could influence short-term investor sentiment. Past earnings calls have had fleeting effects on stock price.

Related Companies

IBSRELAXPHOZAHPHOZEVEL
Conference call scheduled for 8:00 a.m. Eastern Time January 30, 2025 16:30 ET  | Source: Ardelyx, Inc. WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call. About ArdelyxArdelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook. Investor and Media Contacts: Caitlin Lowieclowie@ardelyx.com

Related News